About Engage Bio
Engage Bio is a company based in Santa Clara (United States) founded in 2021 by Kathryn Strobel Kwant and Will Olsen was acquired by Lilly in May 2026. Engage Bio has raised $125 thousand across 1 funding round from investors including Lilly and Y Combinator. Engage Bio offers products and services including Tethosomes. Engage Bio operates in a competitive market with competitors including Moderna, Strand Therapeutics, Immorna, ReviR Therapeutics and Abogen Biosciences, among others.
- Headquarter Santa Clara, United States
- Founders Kathryn Strobel Kwant, Will Olsen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Engage Bio
Engage Bio offers a comprehensive portfolio of products and services, including Tethosomes.
Delivers therapeutic DNA with enhanced expression and reduced toxicity.
People of Engage Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Engage Bio
Engage Bio has successfully raised a total of $125K through 1 strategic funding round. The most recent funding activity was a Seed round of $125 thousand completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Engage Bio
Engage Bio has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Locked | Locked | Locked |
Investor details for Engage Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Engage Bio
Investment portfolio details for Engage Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Engage Bio
Detailed financials for Engage Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Engage Bio Comparisons
Peer comparison for Engage Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Engage Bio
Engage Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Strand Therapeutics, Immorna, ReviR Therapeutics and Abogen Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
mRNA therapeutics platform is provided for multi-functional treatments.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for cancer and diseases are developed.
|
|
| Locked | Locked | Locked |
RNA-based therapeutics for multiple diseases are developed using machine learning.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics are developed for cancer and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule drugs are developed for cancer and inflammatory diseases.
|
Detailed competitors of Engage Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Engage Bio
Complete news archive for Engage Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Engage Bio
Engage Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Engage Bio is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Engage Bio is a funded company, having raised a total of $125K across 1 funding round to date.
Engage Bio was founded in 2021 and is headquartered in Santa Clara, United States. The company operates in the biotechnology sector, where mRNA-based drugs are developed as immunotherapies. These therapies are designed to redirect the immune system toward cancer targets. Focus is placed on advancing treatments for various cancers through immune engagement mechanisms. Co-founders include Kathryn Strobel Kwant and Will Olsen.
Engage Bio's top competitors include Moderna, Strand Therapeutics and Immorna.
Engage Bio offers Tethosomes.
Engage Bio has 2 investors. Key investors include Lilly, and Y Combinator.